

STIC Biotechnology Systems Branch

CRF Problem Report

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 10533, 115
Filing Date: 4-29-05
Date Processed by STIC: 5/12/05

STIC Contact: Mark Spencer: Telephone: 571-272-2510; Fax: 571-273-0221

Nature of Problem:

The CRF (was):

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)
☐ Blank (no files on CRF) (see attached)
☐ Empty file (filename present, but no bytes in file) (see attached)
☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
☐ Not saved in ASCII text
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
☒ Did not contain a Sequence Listing. (see attached sample)
☐ Other: _____

**PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001

<141> 1998-12-31

<150> US 08/999,999

<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1

<211> 389

<212> DNA

<213> Paramecium sp.

<220>

<221> CDS

<222> (279)...(389)

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.

<303> Journal of Genes

<304> 1

<305> 4

<306> 1-7

<307> 1988-06-31

<308> 123456

<309> 1988-06-31

<400> 1

agctgtagtc	attcctgtgt	cctcttctct	ctgggcttct	caccctgcta	atcagatctc	60
agggagagtg	tcttgaccct	cctctgcctt	tgcagcttca	caggcaggca	ggcaggcagc	120
tgatgtggca	attgctggca	gtgccacagg	cttttcagcc	aggcttaggg	tgggttccgc	180
cgcggcgcgg	cggccctctt	cgcgctcttc	tcgcgcctct	ctctcgctct	cctctcgctc	240

(Sample of Submitted File)

10/533,115

5/12/2005

PCT

Sequence Listing

<110> Senju Pharmaceutical Co. Ltd.

<120> A medicine of the corneal disorder

<130> 226-PCT

<140> Prior Application #

<160> 2 Prior Application date

<170> software type

<210> 1

<211> 41

<212> DNA

<213> Artificial Sequence

<400> TGGCCGCTCTT CATTTTCTGC TCGCCGCTCA CTTTGACCAA G 41

<210> 2

<211> 42

<212> DNA

<213> Artificial Sequence

<400> GTGGGCAAGA TGC GCGCTGT GAATGGGGTT GCGCAGCTG TT 42

What's this?

pls
indent

pls
indent

indent 1

move to next line

indent 1

move to next line

pls see Attached

Sample sequence
listings

ggacctgatt aggtgagcag gaggaggggg cagttagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe Ser

ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc caa 344
Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Gln

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Leu

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30

Leu Gln Pro Asn Leu
35

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

<210> 4
<400> 4
000

[Annex VIII follows]